Andrea Alberto Lissoni

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 623 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 456 citations · Full text

Medicine, Gynecology, Oncology +17

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Cathalijne Post, Stephanie M. de Boer, Melanie Powell et al. · International Journal of Radiation Oncology*Biology*Physics · 2020 · 48 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases.

Gerardo Zanetta, D. Trio, Andrea Alberto Lissoni et al. · Radiology · 1993 · 42 citations

Medicine, Gynecology, Surgery +14

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Cathalijne Post, Stephanie M. de Boer, Melanie Powell et al. · The Lancet Oncology · 2025 · 29 citations · Full text

Medicine, Gynecology, Oncology +17